📊 CGEN Key Takeaways
Is Compugen Ltd. (CGEN) a Good Investment?
Insufficient financial data available to conduct meaningful fundamental analysis. Company appears to be pre-revenue or early-stage biotech with no reported revenue, profitability metrics, or balance sheet data in the latest filing period. Critical financial information is required to assess operational performance, financial health, and growth trajectory.
Compugen’s financial health improved materially in 2025, with cash, deposits, and marketable securities rising to about $145.6 million, no meaningful debt, and management stating funding should extend into 2029 under current plans. However, profitability quality is weak because 2025 profit was driven largely by collaboration and royalty-monetization revenue rather than recurring commercial operations, so the core fundamental story still depends on pipeline execution and future partner payments.
Why Buy Compugen Ltd. Stock? CGEN Key Strengths
- Operates in biological products sector with potential for high-value therapeutics
- Listed on Nasdaq indicating regulatory compliance and institutional visibility
- Biotech sector offers potential for transformative clinical breakthroughs
- Very strong liquidity profile with current assets of about $148.0 million against current liabilities of about $22.6 million
- Balance sheet carries no long-term debt burden, limiting financial risk
- R&D spending declined while 2025 operating cash flow turned positive, showing improved cost discipline and partner-funded operations
CGEN Stock Risks: Compugen Ltd. Investment Risks
- No revenue generation reported - indicates pre-commercial or failed product stage
- Complete absence of profitability metrics and financial performance data
- Inability to assess balance sheet strength, liquidity position, or cash burn rate with available data
- No insider buying activity in last 90 days suggests limited management confidence
- Critical data gaps prevent evaluation of operational efficiency and financial stability
- Revenue is highly lumpy and concentrated in milestone, upfront, and royalty-related collaboration payments rather than recurring product sales
- Core operating profitability remains unproven despite 2025 net profit, which was boosted by a large AstraZeneca-related payment
- Biotech execution risk is high because future fundamentals depend on clinical progress, partner decisions, and additional licensing success
Key Metrics to Watch
- Revenue recognition and product commercialization timeline
- Cash position and runway until potential profitability
- Clinical trial progress and regulatory pathway updates
- R&D spending efficiency and pipeline advancement metrics
- Balance sheet composition and debt obligations
- Cash runway and quarterly operating cash burn excluding collaboration upfronts or one-time payments
- Collaboration revenue mix and whether operating income remains positive without major milestone or royalty-monetization events
Compugen Ltd. (CGEN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CGEN Profit Margin, ROE & Profitability Analysis
CGEN vs Healthcare Sector: How Compugen Ltd. Compares
How Compugen Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Compugen Ltd. Stock Overvalued? CGEN Valuation Analysis 2026
Based on fundamental analysis, Compugen Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Compugen Ltd. Balance Sheet: CGEN Debt, Cash & Liquidity
CGEN Revenue Growth, EPS Growth & YoY Performance
CGEN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Compugen Ltd. (CIK: 0001119774)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CGEN
What is the AI rating for CGEN?
Compugen Ltd. (CGEN) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 47% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CGEN's key strengths?
Claude: Operates in biological products sector with potential for high-value therapeutics. Listed on Nasdaq indicating regulatory compliance and institutional visibility. ChatGPT: Very strong liquidity profile with current assets of about $148.0 million against current liabilities of about $22.6 million. Balance sheet carries no long-term debt burden, limiting financial risk.
What are the risks of investing in CGEN?
Claude: No revenue generation reported - indicates pre-commercial or failed product stage. Complete absence of profitability metrics and financial performance data. ChatGPT: Revenue is highly lumpy and concentrated in milestone, upfront, and royalty-related collaboration payments rather than recurring product sales. Core operating profitability remains unproven despite 2025 net profit, which was boosted by a large AstraZeneca-related payment.
What is CGEN's revenue and growth?
Compugen Ltd. reported revenue of N/A.
Does CGEN pay dividends?
Compugen Ltd. does not currently pay dividends.
Where can I find CGEN SEC filings?
Official SEC filings for Compugen Ltd. (CIK: 0001119774) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CGEN's EPS?
Compugen Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CGEN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Compugen Ltd. has a HOLD rating with 47% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CGEN stock overvalued or undervalued?
Valuation metrics for CGEN: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CGEN stock in 2026?
Our dual AI analysis gives Compugen Ltd. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CGEN's free cash flow?
Compugen Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.
How does CGEN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).